MLL-rearranged leukemias have a poor response to standard treatments, including chemotherapy and hematopoietic stem cell transplantation. Unfortunately, these leukemia cells often have an NK-resistant phenotype. We found that this resistance could be overcome by antibody-dependent cell-mediated cytotoxicity (ADCC) against specific antigens expressed by a wide spectrum of clinical MLL-rearranged leukemia, including the pan-B cell marker CD19 and the myeloid marker CD33. Blocking inhibitory KIR signaling further augmented the ADCC activity. This Experimental Design: Three MLL-rearranged leukemia cell lines (RS4;11, SEM, and MV4-11) and primary leukemia blasts were assessed for surface phenotype and susceptibility to NK cell lysis with or without antibodies against CD19 (XmAb5574), CD33 (lintuzumab), or KIR ligands.
Introduction
Recurrent translocations that involve chromosome 11 band q23 have been observed in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and biphenotypic (mixed lineage) leukemia; thus, the gene has been named MLL (for myeloid/lymphoid, or mixed lineage, leukemia) (1) . The MLL gene is a member of the trithorax group and consists of 36 exons encoding a DNA-binding methyltransferase that contains 3,969 amino acids with a molecular weight of 430 kDa (2) . The protein methylates histone H3 on lysine residue 4 (H3K4) for epigenetic control of early embryonic development and hematopoiesis (3, 4) . Chromosomal translocations during leukemogenesis usually involve an 8.3 kb breakpoint cluster region spanning exons 5-11 of MLL, which then join the amino terminal of MLL to the carboxy terminal of one of 70 partner proteins in frame (2, 4) . The common translocations include t (4;11) and t(11;19) in ALL and t(9;11) and t(6;11) in AML, resulting in the formation of fusion proteins, including MLL-AF4, MLL-ENL, MLL-AF9, and MLL-AF6, all of which have lost H3K4 methyltransferase activity (3) . Instead, the chimeric fusion proteins lead to the aberrant expression of many downstream target genes, including HOX, MEIS1, BCL2, C-MYC, and CDK6 (2, 5) .
MLL-rearranged leukemias have unique clinical features and are often associated with a poor prognosis (6) . MLL rearrangements are found in approximately 80% of infant leukemias and in 10% of AML in adults (3) . A very high proportion of patients with therapy-related acute leukemia after treatment with topoisomerase II inhibitors have MLL abnormalities involving AF4, AF9, and ENL, as well as CBP, that are characteristic of therapy-related AML (2, 7) .
Patients with MLL-rearranged leukemia have a low probability of survival, in the 30% to 40% range, even with contemporary chemotherapy and hematopoietic stem cell transplantation (6, 8) .
Because many MLL-rearranged leukemias express mixed-lineage or biphenotypic markers including B and myeloid antigens, targeted therapy using monoclonal antibodies against these antigens is an attractive alternative treatment. Rituximab is an FDA-approved chimeric antibody against human CD20, an antigen expressed beginning at the pre-B-cell stage. Unfortunately, most MLL-rearranged leukemias are stem-cell-like and CD20-negative (3, 4) . Therefore, CD19 is a better target as a pan-B-cell antigen. XmAb5574 is a humanized anti-CD19 antibody with its Fc domain engineered for higher affinity to FcγRIIIa of effector cells and diminished nonspecific binding to FcγIIb. In chronic lymphoblastic leukemia, ALL, and mantle cell lymphoma, it may mediate more effective antibody-dependent cell-mediated cytotoxicity (ADCC) than its parental counterpart as well as other therapeutic antibodies such as rituximab, ofatumumab and alemtuzumab (9) (10) (11) . For pan-myeloid antigens, CD33 is an attractive target. Lintuzumab (also known as SGN-33 and huM195) is an anti-CD33 therapeutic antibody in clinical development (12) . It was reported to promote survival in preclinical mouse models of AML (13, 14) .
Natural killer (NK) cells are the primary lymphocytes that are involved in ADCC through the activation of high-affinity FcγRIIIa (CD16) on their cell surfaces. Human NK cell transplantation has become feasible recently and has therefore generated much interest in augmenting cancer antibody therapy (15) . In a clinical study, NK cell therapy alone was found to be safe and beneficial in AML patients (16) ; however, NK cell transplantation may not always be effective, because immune escape is possible. Biologically, NK cell functions are regulated by two sets of surface molecules: activating and inhibitory receptors. Killer-cell immunoglobulin-like receptors (KIR) and NKG2D are two of the receptor families that are known to be important as inhibitory and activating receptors, respectively, in human leukemia cell recognition. Thus, leukemia cells may escape from NK cell immunosurveillance by upregulation of the expression of a KIR inhibitory ligand or downregulation of NKG2D activation signals. In this study, we characterized the NK cell ligand expression in MLL-rearranged leukemia and provided evidence that ADCC mediated by XmAb5574 or lintuzumab was useful to overcome its inherent NK cell-resistance.
We found that either KIR blockade or selection of a KIR-incompatible donor could further augment ADCC activity in vitro and in vivo.
Materials and Methods

Cell purification
Human peripheral blood mononuclear cells (PBMCs) from healthy donors and primary AML blasts from patients were obtained following informed consent under the approval of the institutional review board of St. Jude Children's Research Hospital. Untouched NK cells were enriched using an NK Cell Isolation Kit (Miltenyi, Auburn, CA) according to the manufacturer's instructions. The purity of the NK cells was more than 95% in all experiments. Human leukemia cells RS4;11 and MV4-11 were from American Type Culture Collection (Manassas, VA). SEM cells were from DSMZ (Braunschweig, Germany). All cell lines were cultured as recommended and passaged with no more than three months. Routine authentication was performed by typical morphology observation. The expression of CD19 and CD33 were continuously monitored by flow cytometry throughout the experimental period to ensure the expression levels were consistent with those at the time of cell line acquisition from suppliers.
Phenotypic analysis by flow cytometry
The following antibodies were purchased from commercial suppliers and used for phenotypic 
KIR genotyping and KIR ligand allele typing
Genotyping of KIR was performed using an Olerup SSP KIR genotyping kit (Olerup SSP AB, Stockholm, Sweden) according to the manufacturer's instructions. Genomic DNA from PBMCs was extracted with a QIAamp DNA blood mini kit (Qiagen Inc., Valencia, CA). The KIRs were PCR-amplified, and the products were electrophoresed in 2% gel. The amplified KIR alleles were determined according to the expected product sizes. KIR ligand typing was performed using a single-nucleotide polymorphism assay following an allelic discrimination assay protocol (Applied Biosystems, Life Technologies, Carlsbad, CA) as previously described (17) . The 
Statistical analysis
Comparisons between means in two groups were based on a 2-tailed nonparametric test. For comparisons of means in more than two groups, one-way ANOVA was used. The difference was considered statistically significant if p < 0.05.
Results
NK-resistant phenotype in MLL-rearranged leukemia cell lines
The absence of CD20 in leukemia cells is one of the known mechanisms for rituximab resistance. In this study, we used three MLL-rearranged cell lines (RS4;11, SEM, and MV4-11) that were CD20 
Anti-CD19 and anti-CD33 antibodies induced ADCC effectively against MLL-rearranged leukemia
Because FcγIIIa is a potent NK cell activating receptor, we hypothesized that all of the NKresistant mechanisms in MLL-rearranged leukemia could be overridden by activating FcγIIIa through monoclonal antibodies against leukemia-associated antigens. To test the hypothesis, we used two therapeutic antibodies that can trigger FcγIIIa, including one against CD19 and the other against CD33 antigen. With the anti-CD19 antibody (XmAb5574), there was a dosedependent cytotoxicity against CD19 Figure 1) . When panMHCI antibody was used alone, there was minimal lysis of MLL-rearranged leukemia cells in all experiments, confirming prior observations that removing KIR inhibition alone was insufficient for NK cell activation (Figure 2 ). We also examined the effect of XmAb5574 or lintuzumab with or without panMHCI on a primary biphenotypic leukemia sample using saturating dose of the two antibodies ( Figure 4E ). Phenotyping showed that the surface expression of CD19 in the blasts was lower than that of SEM, but the expression of CD33 was similar. We observed minimal cytotoxicity on the blasts when XmAb5574 or 
lintuzumab was used alone. However, when panMHCI antibody was added, the cytotoxicity from lintuzumab-or XmAb5574-induced ADCC significantly increased (p<0.05 for both cases).
Cytotoxicity followed the rule of missing-self recognition
Because a KIR-specific antibody is not yet available clinically, we sought to determine whether the ADCC mediated by lintuzumab or XmAb5574 followed the rule of missing-self recognition and whether a KIR-mismatched NK cell donor might therefore be preferable. In the subsequent experiments, NK cells were obtained from donors positive for all three classes of KIR (KIR2DL1, KIR2DL2/3, and KIR3DL1). The MV4-11 cells had the ligands for KIR2DL1 and KIR2DL2/3 but not for KIR3DL1 (Table 1 ). When MV4-11 cells were treated with 1000 ng/mL lintuzumab, the KIR3DL1 subset degranulated the most, with minimal change after the addition of panMHCI antibody ( Figure 5A ). Both KIR2DL1 and KIR2DL2/3 subsets degranulated less, but when panMHCI antibody was included, the degranulation for these groups increased to a level comparable to that of the KIR3DL1 subset (p<0.05 and p<0.01, respectively). 
use of NK cells from a KIR-mismatched donor or the use of KIR-blocking antibody could synergize with ADCC therapy targeting CD19 or CD33.
Role of FcγIIIa polymorphism and activating KIR
A single-nucleotide polymorphism is present at amino acid position 158 (Val or Phe) of the FcγRIIIa receptor, with 158V reported to have a higher affinity for IgG and associated with increased ADCC efficacy (18). We genotyped our cohort of donor NK cells and found that there was no correlation between 158V and ADCC activity in our experiments (data not shown). We also found no statistical correlation between donor activating KIR-S repertoire and ADCC activity (data not shown).
Blocking KIR ligand increased disease-free survival induced by ADCC in a mouse model
We used a mouse model to determine whether the ADCC induced by XmAb5574 or lintuzumab could benefit host survival in MLL-rearranged leukemia. To accurately estimate the leukemia burden during disease progression, we used the luciferase bioluminescence system. The susceptibility of the luciferase-transduced SEM cell line to NK cell lysis in vitro remained the same as that of untransduced cells ( Supplementary Figure 2A and B) . We chose SEM as the cell model because it is a typical MLL cell line that expresses the least activating NK cell ligands and expressed both CD19 and CD33 antigens. We injected 5×10 found that day 15 was the earliest time suitable for cross-sectional analysis and for comparison of bioluminescence intensity among the treatment groups. For the mice treated with lintuzumab, the median bioluminescence signal from the ventral side of the animals was 1.44 logs lower than that of untreated control mice ( Figure 6A, left panel) . However, a statistically significant decrease (3.59 logs) was observed when panMHCI antibody was injected as well (p<0.001 compared with the NK-alone group). Similar results were obtained on the bioluminescence signals from the dorsal side of the mice ( Figure 6A, right panel) . For the mice treated with XmAb5574, the median bioluminescence signal from the ventral side of the mice decreased 1.66 logs compared with that from untreated mice. A significant decrease in signals (3.25 logs) was observed in the mice that also received panMHCI antibody (p<0.001, Figure 6B ). A similar pattern was observed on the dorsal side of the mice. In terms of survival, the mice treated with NK cells alone (n=10) or NK+lintuzumab (n=10) survived significantly longer than untreated mice (SEM alone) (p=0.02 and p=0.0004, respectively) ( Figure 6C ). However, all of these mice eventually succumbed to disease. Remarkably, 9 of 10 mice treated with NK cells+lintuzumab+panMHCI antibodies survived long-term; thus their survival was significantly longer than that of the mice given SEM alone (p<0.0001), SEM+NK cells (p<0.0002), or SEM+NK cells+lintuzumab (p=0.0003). Additionally, mice that received NK cells+XmAb5574 also survived significantly longer (p=0.0477, Figure 6D ). With the addition of panMHCI, 5 of 5 mice survived long-term (p=0.0019 compared with the SEM-alone group). Lintuzumab is a humanized anti-CD33 antibody. It prolonged the survival of mice with acute myeloid leukemia in preclinical studies (14) . In a recent phase III multicenter clinical trial, it was found that it was safe but failed to improve patient survival (12) . However, the therapeutic effects of lintuzumab could be improved when it was used together with 5-azacytidine (13).
Gemtuzumab ozogamicin, another anti-CD33 antibody, has been showed to produce complete molecular remission in a patient with MLL-AF9 AML (19). In this study, lintuzumab triggered dose-response ADCC activity on CD33 
